Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Precision Biosciences (DTIL) Non-Current Deffered Revenue (2018 - 2025)

Precision Biosciences has reported Non-Current Deffered Revenue over the past 8 years, most recently at $20.0 million for Q3 2025.

  • Quarterly Non-Current Deffered Revenue fell 24.92% to $20.0 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $20.0 million through Sep 2025, down 24.92% year-over-year, with the annual reading at $23.3 million for FY2024, 68.12% down from the prior year.
  • Non-Current Deffered Revenue was $20.0 million for Q3 2025 at Precision Biosciences, down from $20.2 million in the prior quarter.
  • Over five years, Non-Current Deffered Revenue peaked at $131.2 million in Q1 2021 and troughed at $20.0 million in Q3 2025.
  • The 5-year median for Non-Current Deffered Revenue is $73.1 million (2023), against an average of $63.6 million.
  • Year-over-year, Non-Current Deffered Revenue skyrocketed 99.05% in 2021 and then plummeted 72.58% in 2025.
  • A 5-year view of Non-Current Deffered Revenue shows it stood at $67.0 million in 2021, then increased by 23.66% to $82.9 million in 2022, then dropped by 11.81% to $73.1 million in 2023, then tumbled by 68.12% to $23.3 million in 2024, then dropped by 14.35% to $20.0 million in 2025.
  • Per Business Quant, the three most recent readings for DTIL's Non-Current Deffered Revenue are $20.0 million (Q3 2025), $20.2 million (Q2 2025), and $20.5 million (Q1 2025).